SCHEDULE 13G/A: BlackRock Maintains Significant 7.6% Stake in VAXCYTE, Inc. Common Stock

BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 7.6% of VAXCYTE, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 9,825,638 shares of VAXCYTE, Inc. common stock.
• This represents 7.6% of VAXCYTE, Inc.'s outstanding common stock.
• BlackRock holds sole voting power over 9,688,274 shares and sole dispositive power over all 9,825,638 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported ownership stake.
• BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of VAXCYTE, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a 13G is a routine disclosure, the continued significant stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence, even if passive. There are no negative implications within the document itself.

Positives

• The continued significant beneficial ownership by a major institutional investor like BlackRock (7.6%) may signal ongoing institutional confidence in VAXCYTE, Inc.

Risks

• This Schedule 13G filing primarily concerns beneficial ownership disclosure and does not contain information regarding VAXCYTE, Inc.'s operational, financial, or strategic risks.

Future Outlook

The document does not provide a future outlook for VAXCYTE, Inc.'s business operations or financial performance. It states that BlackRock's acquisition and holding of securities are in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a routine disclosure by BlackRock, one of the world's largest asset managers, regarding its passive investment stake in VAXCYTE, Inc. Such filings are common for institutional investors holding significant positions and indicate ongoing market participation and portfolio management within the biotechnology or pharmaceutical sector, where VAXCYTE operates.

Comparison to Industry Standards

• This document is a regulatory compliance filing (Schedule 13G) by an institutional investor, BlackRock, Inc., disclosing its beneficial ownership in VAXCYTE, Inc. It does not contain financial or operational performance data for VAXCYTE, Inc. that would allow for a direct comparison to industry standards for company results or projects.
• The filing confirms BlackRock's adherence to SEC disclosure requirements for significant passive ownership stakes, which is standard practice for large asset management firms.

Corporate Governance

Stakeholder Impact

• Shareholders of VAXCYTE, Inc. may view BlackRock's continued significant stake as a positive signal of institutional interest and stability in the company's stock.
• The filing provides transparency to the market regarding a major institutional holder's position, which benefits all stakeholders by ensuring compliance with disclosure regulations.

Next Steps

• BlackRock, Inc. will continue to monitor its beneficial ownership in VAXCYTE, Inc. and file further amendments or new Schedule 13G/D reports as required by SEC regulations if its ownership percentage or investment intent changes.

Key Dates

Keywords

VAXCYTE, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake